Drugs / sB24M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04895566 | May 2021 → Mar 2023 | pemphigus vegetans, pyoderma gangrenosum | SWISS BIOPHARMA MED GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sB24M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895566 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody (Mab) sB24M” NCT04895566 ↗ |